Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371993 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4GRIN2BPRCPSIGMAR1 | |
| SCHEMBL12372000 | 0.80 | SIGMAR1 (0.47) | CHRNB2CHRNA4SIGMAR1CYP2D6HTR2A | |
| SCHEMBL12371998 | 0.80 | SIGMAR1 (0.44) | CHRNB2CHRNA4SIGMAR1HTR2AHTR2C | |
| SCHEMBL20245626 | 0.78 | OPRM1 (0.42) | SIGMAR1OPRM1CYP3A4CYP2D6DRD2 | |
| SCHEMBL12105074 | 0.77 | MTNR1B (0.40) | GRIN2B | |
| SCHEMBL12105124 | 0.77 | MTNR1B (0.40) | GRIN2B | |
| SCHEMBL12105122 | 0.77 | MTNR1B (0.40) | GRIN2B | |
| SCHEMBL18408066 | 0.76 | GRIN2B (0.40) | CHRNB2CHRNA4GRIN2BOPRM1 | |
| SCHEMBL12371996 | 0.76 | DRD2 (0.39) | GRIN2BSIGMAR1OPRM1HTR2AHTR2C | |
| SCHEMBL12371994 | 0.76 | SIGMAR1 (0.41) | SIGMAR1OPRM1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932349-B2 | 8-carboxamido-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | HRH4, HRH2, HRH3 | CHRNB2 573/4885CHRNA4 289/4885GRIN2B 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.